Hydrocodone
- HYDROCODONE
- Dihydrocodeinone
- Hydrocodon
- Hydrocone
- Hydroconum
- Create:2005-03-26
- Modify:2025-01-11
- Codinovo
- Dicodid
- Dihydrocodeinone
- Hycodan
- Hycon
- Hydrocodeinonebitartrate
- Hydrocodon
- Hydrocodone
- Hydrocodone Bitartrate
- Hydrocodone Tartrate (1:1), Hydrate (2:5)
- Hydrocon
- Robidone
- HYDROCODONE
- Dihydrocodeinone
- Hydrocodon
- Hydrocone
- Hydroconum
- Multacodin
- Bekadid
- Codinovo
- 125-29-1
- Idrocodone
- (-)-Dihydrocodeinone
- DICO
- hidrocodona
- Hydrocodonum
- Idrocodone [DCIT]
- Dicodid
- Codeinone, dihydro-
- Hydrocodonum [INN-Latin]
- Hidrocodona [INN-Spanish]
- 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
- 6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan
- HSDB 3097
- UNII-6YKS4Y3WQ7
- 4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
- EINECS 204-733-9
- 6YKS4Y3WQ7
- NSC 19044
- Hydrocodone (INN)
- BRN 0094193
- CHEBI:5779
- HYDROCODONE-
- NSC-19044
- DTXSID8023131
- Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)-
- 4-27-00-03580 (Beilstein Handbook Reference)
- 3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one
- Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-
- Morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl-
- HYDROCODONE [INN]
- Hydrocodonum (INN-Latin)
- Hidrocodona (INN-Spanish)
- Hydrocodone [INN:BAN]
- (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
- Hydrocodone polistirex
- HYDROCODONE CII (USP-RS)
- HYDROCODONE CII [USP-RS]
- NCGC00159317-02
- 4,5.alpha.-Epoxy-3-methoxy-17-methylmorphinan-6-one
- DIHYDROCODEINE HYDROGEN TARTRATE IMPURITY C (EP IMPURITY)
- DIHYDROCODEINE HYDROGEN TARTRATE IMPURITY C [EP IMPURITY]
- opioid1
- DEA No. 9193
- Hydrocodonum (Latin)
- HYDROCODONE CII
- BEKADID-
- DICODID-
- HYDROCODONE [MI]
- HYDROCODONE [HSDB]
- HYDROCODONE [VANDF]
- SCHEMBL2987
- CHEMBL1457
- HYDROCODONE [WHO-DD]
- Hydrocodone polistirex [USAN]
- Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5.alpha.)-
- DTXCID803131
- GTPL7081
- Hydrocodone, 1mg/ml in Methanol
- R05DA03
- (5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one
- Hydrocodone 0.1 mg/ml in Methanol
- Hydrocodone 1.0 mg/ml in Methanol
- BDBM50386689
- Hydrocodone (1.0mg/mL in Methanol)
- DB00956
- NCGC00159317-03
- DB-243593
- NS00009201
- C08024
- D08045
- Q411441
- 17-methyl-4,5alpha-epoxy-3-methoxymorphinan-6-one
- 4,5alpha-epoxy-3-methoxy-17-methyl-morphinan-6-one
- Morphinan-6-one,5.alpha.-epoxy-3-methoxy-17-methyl-
- OXYCODONE HYDROCHLORIDE IMPURITY E [EP IMPURITY]
- OXYCODONE HYDROCHLORIDE, HYDROCODONE- [USP IMPURITY]
- Morphinan-6-one,5-epoxy-3-methoxy-17-methyl-, (5.alpha.)-
- (5.ALPHA.)-3-METHOXY-17-METHYL-4,5-EPOXYMORPHINAN-6-ONE
- WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ JO1 P1
- 4aH-8,5-bcd]furan-5-(6H)-one, 7,7a,8,9-tetrahydro-3-methoxy-12-methyl-
- (1S,5R,13R,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one
- (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one
- 50678-79-0
172.49 Ų [M+Na]+
168.06 Ų [M+H]+
300.16357 100
199.08586 34.67
213.09396 10.32
241.0919 9.26
183.08472 7.82
171.0803 100
128.062 83.11
141.0698 71.88
153.0698 67.06
199.0752 62.58
300.1592 999
199.0747 2
285.1349 1
300.1593 999
199.0752 29
243.1015 15
241.0858 9
257.1174 5
- Hydrocodone Bitartrate (has salt form)
- Benzhydrocodone Hydrochloride (is active moiety of)
- Hydrocodone hydrochloride (is active moiety of)
(Trade Names:Vicodin®, Lortab®, Lorcet-HD®, Hycodan®, Vicoprofen®)
Use (kg) in USA (2002): 28600
Consumption (g per capita) in the USA (2002): 0.101
Calculated removal (%): 9.7
H302 (97.6%): Harmful if swallowed [Warning Acute toxicity, oral]
H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]
H334 (100%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]
H400 (97.6%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]
P233, P260, P261, P264, P270, P271, P272, P273, P280, P284, P301+P317, P302+P352, P304+P340, P321, P330, P333+P317, P342+P316, P362+P364, P391, P403, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 42 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Acute Tox. 4 (97.6%)
Skin Sens. 1 (100%)
Resp. Sens. 1 (100%)
Aquatic Acute 1 (97.6%)
Despite wide scale use for many decades, hydrocodone by itself has not been convincingly linked to instances of clinically apparent acute liver injury. However, when combined with acetaminophen, hydrocodone combinations have become a common cause of acetaminophen acute liver injury. The typical history is of a patient who began taking more than the prescribed number of pills over several days, attempting to achieve more of an opiate effect and leading secondarily and unintentionally to an overdose of acetaminophen. Because of their potential for hepatotoxicity, opioid combinations in which the dose of acetaminophen is greater than 325 mg per tablet or capsule were discontinued.
Hydrocodone, like other opiates, is metabolized in the liver by the P450 microsomal oxidizing enzyme system, and levels can be significantly affected by either inhibitors of CYP 3A4 (which increase levels and can lead to toxicity) or inducers of the enzyme (which decrease levels and can affect efficacy).
Likelihood score: E (unlikely cause of clinically apparent liver injury).
References on the safety and potential hepatotoxicity of hydrocodone are given in the Overview section of the Opioids.
Drug Class: Opioids
◉ Summary of Use during Lactation
Hydrocodone is an opioid narcotic. Benzhydrocodone is a hydrocodone prodrug that is rapidly converted into hydrocodone in the gastrointestinal tract. Maternal use of oral opioids during breastfeeding can cause infant drowsiness, which may progress to rare but severe central nervous system depression. Newborn infants seem to be particularly sensitive to the effects of even small dosages of narcotic analgesics. If hydrocodone is required by the mother of a newborn, it is not a reason to discontinue breastfeeding; however, once the mother's milk comes in, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of oral hydrocodone to 2 to 3 days at a maximum dosage of 30 mg daily with close infant monitoring. If the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately.
◉ Effects in Breastfed Infants
The 18-day-old infant of a breastfeeding mother became groggy and "slept for most of the day" while the mother was taking 20 mg of oral hydrocodone combined with 1300 mg of acetaminophen every 4 hours for painful nipple candidiasis and mastitis. The mother decreased her dose by one-half and the infant apparently no longer experienced grogginess or hypersomnolence.[3] The infant's symptoms were probably due to the maternal hydrocodone.
A 5-week-old breastfed infant became cyanotic and required mouth-to-mouth resuscitation and intubation. The infant's urine was positive for opioids and the infant responded positively to naloxone; the level of consciousness improved over 2 days and extubation was accomplished. The infant's mother admitted to taking a hydrocodone-acetaminophen combination product and methadone that had been prescribed for migraine headache before she was breastfeeding.[4] The infant's symptoms were probably due to the maternal opiate use.
◉ Effects on Lactation and Breastmilk
Narcotics can increase serum prolactin.[5] However, the prolactin level in a mother with established lactation may not affect her ability to breastfeed.
◈ What is hydrocodone?
Hydrocodone is an opioid medication that has been used to treat pain. Opioids are sometimes called narcotics. Some commonly used hydrocodone products also contain other medications, such as acetaminophen. Brand names for these combination products include Lortab®, Norco®, and Vicodin®. For more information on acetaminophen, please see our fact sheet: https://mothertobaby.org/fact-sheets/acetaminophen-pregnancy/.Sometimes when people find out they are pregnant, they think about changing how they take their medication, or stopping their medication altogether. However, it is important to talk with your healthcare providers before making any changes to how you take your medication. Your healthcare providers can talk with you about the benefits of treating your condition and the risks of untreated illness during pregnancy.If you have been taking hydrocodone regularly or have a dependency or opioid use disorder, you should not stop taking the medication suddenly. Stopping an opioid medication suddenly could cause you to go into withdrawal. It is not known if or how withdrawal might affect a pregnancy. It is suggested that any reduction in hydrocodone be done slowly, and under the direction of your healthcare provider.
◈ I am taking hydrocodone, but I would like to stop taking it before getting pregnant. How long does the drug stay in my body?
People eliminate medication at different rates. In healthy adults, it takes up to 24 hours, on average, for most of the hydrocodone to be gone from the body.
◈ I take hydrocodone. Can it make it harder for me to get pregnant?
It is not known if using hydrocodone could make it harder to get pregnant. The results from a limited number of studies on the use of opioids during pregnancy are mixed and do not clearly show if opioids could make it harder to get pregnant.
◈ Does taking hydrocodone increase the chance of miscarriage?
Miscarriage is common and can occur in any pregnancy for many different reasons. There are no published studies that have looked at the link between the use of hydrocodone and the chance of miscarriage. Some studies on the use of other opioids suggest an increased chance of miscarriage while other studies do not.
◈ Does taking hydrocodone increase the chance of birth defects?
Every pregnancy starts out with a 3-5% chance of having a birth defect. This is called the background risk. It is not known if taking hydrocodone during pregnancy increases the chance of birth defects. Two studies reported that taking hydrocodone in the first trimester increased the chance of heart defects. One of the studies also reported a small increased chance of spina bifida (an opening in the spine and spinal cord) and gastroschisis (an opening in the wall of the abdomen). However, the number of pregnancies exposed to hydrocodone in these studies was small and these studies have not found a specific pattern of birth defects caused by hydrocodone. Two other studies on hydrocodone did not find an increased chance of birth defects. It is possible that other factors, such as other exposures, a combination of exposures, or the condition causing the pain could have been responsible for the birth defects reported. Based on the published information, if there is an increased chance of birth defects with opioid use in pregnancy, it is likely to be small.
◈ Does taking hydrocodone in pregnancy increase the chance of other pregnancy-related problems?
One study found that people who used hydrocodone and other opioids in pregnancy were more likely to have babies that were born smaller than expected. However, the people in this study who used opioids were also more likely to smoke cigarettes during pregnancy, which can also cause babies to be born small.Studies involving people who often use some opioids during their pregnancy have found an increased chance for pregnancy-related problems, including poor growth of the baby, low levels of amniotic fluid (fluid that surrounds baby in uterus), stillbirth, preterm delivery (birth before week 37), and C-section. This is more commonly reported in those who are taking heroin or who are using prescribed opioid medication in greater amounts or for longer than recommended by their healthcare provider. Use of an opioid close to the time of delivery can result in withdrawal symptoms in the baby (see the section of this fact sheet on neonatal abstinence syndrome).
◈ Will my baby have withdrawal (neonatal abstinence syndrome) if I continue to take hydrocodone?
Neonatal abstinence syndrome (NAS) is the term used to describe withdrawal symptoms in newborns from opioid medication(s) that a person takes during pregnancy. NAS symptoms can include irritability, crying, sneezing, stuffy nose, poor sleep, extreme drowsiness (very tired), yawning, poor feeding, sweating, tremors, seizures, vomiting, and diarrhea. Most often, symptoms of NAS appear 2 days after birth and may last more than 2 weeks. The chance that NAS will occur depends on the length of time and/or the dose of opioid taken during pregnancy, if other medications were also taken, if baby was born preterm, and/or size of the baby at birth. If opioids were taken in pregnancy, it is important to let your baby’s healthcare providers know so that they can check for symptoms of NAS and provide the best care for your newborn.Studies have reported a risk for neonatal abstinence syndrome (NAS) with some opioids; however, not all medications in this class have been studied. Based on what we know about the chance of NAS with other opioids, it is likely that hydrocodone also has a chance for NAS. Because information is limited, it is not known if the chance is higher or lower with hydrocodone than with other, better studied opioids.
◈ Does taking hydrocodone in pregnancy affect future behavior or learning for the child?
It is not known if hydrocodone increases the chance for behavior or learning issues. Some studies on opioids as a general group have found more problems with learning and behavior in children exposed to opioids for a long period of time during pregnancy. It is hard to tell if this is due to the medication exposure or other factors that may increase the chances of these problems.
◈ What if I have an opioid use disorder?
Studies find that people who are pregnant and take opioids in higher doses or for longer than recommended by their healthcare providers (i.e. misuse or “abuse” opioids) have an increased chance for pregnancy problems. These include poor growth of the baby, stillbirth, preterm delivery, and need for a C-section.
◈ What screenings or tests are available to see if my pregnancy has birth defects or other issues?
Prenatal ultrasounds can be used to screen for some birth defects. Ultrasound can also be used to monitor the growth of the pregnancy. Talk with your healthcare provider about any prenatal screenings or testing that are available to you. There are no tests available during pregnancy that can tell how much effect there could be on future behavior or learning.
◈ Hydrocodone and breastfeeding:
Speak to your healthcare provider about your pain and medications that may be used while you are breastfeeding. While the amounts of hydrocodone that get into breast milk are very small, some babies might have problems with those small amounts. Talk with your healthcare provider or a MotherToBaby specialist about your specific medication, as information on breastfeeding might change based on your specific situation such as the age of your baby, the dose of medication, and other factors.The use of some opioids in breastfeeding might cause babies to be very sleepy and have trouble latching on. Some opioids can cause trouble with breathing. If you are using any opioid, talk to your healthcare provider about how to use the least amount for the shortest time and how to monitor (watch) your baby for any signs of concern. Contact the baby’s healthcare provider immediately if your baby has any problems such as increased sleepiness (more than usual), trouble feeding, trouble breathing, or limpness. Be sure to talk to your healthcare provider about all your breastfeeding questions.
◈ If a male takes hydrocodone, could it affect fertility or increase the chance of birth defects?
It is not known if hydrocodone could affect male fertility (ability to get partner pregnant) or increase the chance of birth defects above the background risk. Use or misuse of opioids in general has been shown to lower fertility in males. In general, exposures that fathers or sperm donors have are unlikely to increase risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/.
- US9265760
- US6599531
- US6348216
- US6228398
- US8309060
- US6488963
- US9060940
- US8808740
- US6733783
- US9095614
- US9095615
- US8361499
- US9084816
- US9205056
- US8647667
- US9198863
- US9289391
- US9056052
- US8529948
- US8551520
- US9023401
- US9326982
- US6902742
- US9132096
- US9492389
- US9492391
- US9549907
- US9572804
- US9669023
- US9486412
- US9669024
- US9572779
- US9486413
- US9517236
- US9492390
- US9675611
- US9682077
- US9545380
- US9333201
- US9610286
- US9452163
- US9486451
- US9339499
- US9421200
- US9433619
- US9675610
- US9572803
- US9216176
- US8445018
- US9713611
- US9763933
- US9770416
- US9775809
- US9750703
- US9861584
- US9872837
- US10028946
- US10092559
- US10130591
- US9808431
- US10105324
- US10369109
- US10322120
- US10456393
- US10722511
- US11304909
- US11304908
- US11844865
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=LLPOLZWFYMWNKH-CMKMFDCUSA-N
- Avoid alcohol. Profound CNS depression, including sedation, respiratory depression, coma, and death may occur.
- Take with or without food. Cmax and AUC are not altered by food in a clinically significant way.
- BindingDBLICENSEAll data curated by BindingDB staff are provided under the Creative Commons Attribution 3.0 License (https://creativecommons.org/licenses/by/3.0/us/).https://www.bindingdb.org/rwd/bind/info.jsp
- Comparative Toxicogenomics Database (CTD)LICENSEIt is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.http://ctdbase.org/about/legal.jsp
- Drug Gene Interaction database (DGIdb)LICENSEThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.http://www.dgidb.org/downloadsHYDROCODONEhttps://www.dgidb.org/drugs/rxcui:5489
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useHydrocodonehttps://www.drugbank.ca/drugs/DB00956
- IUPHAR/BPS Guide to PHARMACOLOGYLICENSEThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)https://www.guidetopharmacology.org/about.jsp#licenseGuide to Pharmacology Target Classificationhttps://www.guidetopharmacology.org/targets.jsp
- Therapeutic Target Database (TTD)
- Toxin and Toxin Target Database (T3DB)LICENSET3DB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (T3DB) and the original publication.http://www.t3db.ca/downloadsHydrocodonehttp://www.t3db.ca/toxins/T3D2941
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/
- ChemIDplusHydrocodone [INN:BAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0000125291ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- DTP/NCILICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuse
- EPA DSSToxCompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-noticeHydrocodone (EC: 204-733-9)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/60955
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Hazardous Substances Data Bank (HSDB)
- Human Metabolome Database (HMDB)LICENSEHMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.http://www.hmdb.ca/citingHydrocodonehttp://www.hmdb.ca/metabolites/HMDB0015091HMDB0015091_msms_2226355https://hmdb.ca/metabolites/HMDB0015091#spectra
- CCSbaseCCSbase Classificationhttps://ccsbase.net/
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/HydrocodoneNORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- ChEBI
- Drug Enforcement Administration (DEA)LICENSEUnless otherwise indicated, information on Department of Justice websites is in the public domain and may be copied and distributed without permission. Citation of the Department of Justice as source of the information is appreciated, as appropriate.https://www.justice.gov/legalpoliciesDEA drug and chemical classificationhttps://www.dea.gov/drug-information/drug-scheduling
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Pharmacological Classificationhttps://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
- LiverTox
- LOTUS - the natural products occurrence databaseLICENSEThe code for LOTUS is released under the GNU General Public License v3.0.https://lotus.nprod.net/Hydrocodonehttps://www.wikidata.org/wiki/Q411441LOTUS Treehttps://lotus.naturalproducts.net/
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licence
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- DailyMed
- Drugs and Lactation Database (LactMed)
- Mother To Baby Fact SheetsLICENSECopyright by OTIS. This work is available under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license (CC BY-NC-ND 3.0).https://www.ncbi.nlm.nih.gov/books/about/copyright/
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- EPA Chemical and Products Database (CPDat)EPA CPDat Classificationhttps://www.epa.gov/chemical-research/chemical-and-products-database-cpdat
- FDA Orange BookLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.keg
- Natural Product Activity and Species Source (NPASS)
- MassBank Europe
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- Metabolomics Workbench
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmlhydrocodonehttps://rxnav.nlm.nih.gov/id/rxnorm/5489
- PharmGKBLICENSEPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).https://www.pharmgkb.org/page/policieshydrocodonehttps://www.pharmgkb.org/chemical/PA449900
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/abouthydrocodonehttps://pharos.nih.gov/ligands/MF57RNLX14JZ
- SpectraBaseHydrocodonehttps://spectrabase.com/spectrum/4UFANbFsEdHHydrocodonehttps://spectrabase.com/spectrum/1pD8zkjPQVDHydrocodonehttps://spectrabase.com/spectrum/LMv8os3edD5Dihydrocodeinonehttps://spectrabase.com/spectrum/Cr1uPbR8tPVDihydrocodeinonehttps://spectrabase.com/spectrum/MkEGhbjbWB
- Springer Nature
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- USGS Health-Based Screening Levels for Evaluating Water-Quality DataLICENSEhttps://www.usgs.gov/legal
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/
- Wikidatahydrocodonehttps://www.wikidata.org/wiki/Q411441
- WikipediaHydrocodonehttps://en.wikipedia.org/wiki/Hydrocodone
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlHydrocodonehttps://www.ncbi.nlm.nih.gov/mesh/68006853Antitussive Agentshttps://www.ncbi.nlm.nih.gov/mesh/68000996Analgesics, Opioidhttps://www.ncbi.nlm.nih.gov/mesh/68000701
- PubChem
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- EPA Substance Registry ServicesEPA SRS List Classificationhttps://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 403452073https://pubchem.ncbi.nlm.nih.gov/substance/403452073
- NCBI